RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Analysts and consensus

Analyst Coverage

SEBChristopher Uhdechristopher.uhde@seb.se+46 876 385 53Stockholm
RBCCoverage suspended
ABG Sundal CollierGonzalo Artiach CastañónGonzalo.Artiach@abgsc.se+46 73 321 73 96  Stockholm
RedeyeJohan Unnerusjohan.unnerus@redeye.se+46 724 023 385Stockholm
Van Lanschot KempenSuzanne van Voorthuizen


+31 6 29 71 3490

CarnegieErik Hultgårderik.hultgard@carnegie.se+46 (0)8 5886 9237Stockholm
Intron Health ResearchNaresh ChouhanNaresh@IntronHealthResearch.com+44 7939 224 322London
Ökonomisk UgebrevLars Hatholthatholt@outlook.com+45 22 23 78 15Copenhagen
Erik Penser BankLudvig Svenssonludvig.svensson@penser.se+46 (0) 84 638 059Stockholm
H.C. Wainwright & Co.Douglas Tsaodtsao@hcwresearch.com+1 212 916 3968New York City
William BlairMatt Phippsmphipps@williamblair.com+1 312 364 8602Chicago
Bryan, Garnier & Co.Ingrid Gafanhaoigafanhao@bryangarnier.comParis

Analyst Consensus

Updated 07-14-2023

   Patient uptake, EURevenue estimates, SEKmEBIT, SEKmOperating Cash Flow, SEKmCash position, SEKm
Consensus modelPrice target, SEKWACCQ2'23eFY'23eFY'24eFY'25eQ2'23eFY'23eFY'24eFY'25eQ2'23eFY'23eFY'24eFY'25eQ2'23eFY'23eFY'24eFY'25eQ2'23eFY'23eFY'24eFY'25e
High 24413%1069180246432585252,902-169-471-149808-130-530-1808161,1471,6102,0542,958
Number of contributions7758875888588828882888

Hold 0
Sell 0

This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on a collection of estimates done on a quarterly basis. Any opinions, forecasts, estimates, projections or predictions regarding Hansa Biopharma’s performance made by the analysts (and, therefore, the consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Hansa Biopharma or its management. Hansa Biopharma does not by providing these estimates imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations made or provided by such analysts. Hansa Biopharma assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.